GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 100 6. Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard? Your company is committed to managing and reducing the environmental impacts of its operations and products across their lifecycle globally. Since the pharmaceutical industry is regulated with respect to impact on the environment, there are no significant adverse impacts to the environment. Your company has obtained the consent to operate under the pollution control limits set by the pollution control boards and we report on the same periodically. Also, your company follows Good Manufacturing Practices which mitigate some of the risks in this regard. The contract manufacturers and suppliers are assessed at the time of onboarding and periodically for compliance with these issues. 7. Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts. • Our key contract manufacturers are assessed for their environmental impacts once in 3 years. An environment assessment was initiated during the financial year for 3 contract manufacturers to evaluate the release of Albendazole in the environment. • The contract manufacturers are also assessed for water risk based on Site’s current water profile, analysis based on the Aqueduct tool & WWF water risk assessment tool, and CGWA (Central ground water authority) requirements. Based on this, a detailed assessment of the contract manufacturers in high water risk areas is undertaken and actions are taken to reduce water consumption, relocate them or to find an alternate solution. • Further a programme is implemented to reduce the environmental footprint from the production of antibiotics at the third- party contract manufacturers’ site by controlling the release of antibiotics into the environment within the science-driven risk-based discharge limits. This is also in accordance with the AMR Industry Alliance Common Manufacturing Framework (GSK is a signatory of the AMR Industry Alliance which is one of the largest private sector coalitions set up to provide sustainable solutions to curb Antimicrobial Resistance (AMR)) and wastewater discharge limits 3.7. Principle 7: Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent We are committed to advocating for policies that protect the interests of patients, our business and the pharmaceutical sector in India. We actively engage with various industrial, trade and government bodies and are a part of various task forces and sub-committees on sector-specific critical issues such as drug pricing and clinical trials. Our code of conduct is a critical guiding document that enables us to maintain our interactions with these associations with transparency and with integrity. As responsible corporate citizen, we do not make any political contributions. Essential Indicators 1. a. Number of affiliations with trade and industry chambers/ associations. b. List the top 10 trade and industry chambers/ associations (determined based on the total members of such a body) the entity is a member of/ affiliated to. S. No. Name of the trade and industry chambers/ associations Reach of trade and industry chambers/ associations (State/National) 1 Organization of Pharmaceutical Producers of India (OPPI) National 2 Confederation of Indian Industry (CII) National 3 Federation of Indian Chambers of Commerce and Industry (FICCI) National 4 India Business Councils of US (USIBC) and UK (UKIBC) Global 5 European Federation of Pharmaceutical Industries and Associations (EFPIA) India network National, Global 6 Indian society for clinical research (ISCR) National Business Responsibility and Sustainability Report